Close Menu

CareDx

The GenomeWeb Index outperformed the Dow Jones and the Nasdaq, but underperformed the Nasdaq Biotechnology Index this month.

AlloSure 3.0 can diagnose the very early stages of T-cell mediated rejection, allowing clinicians to begin anti-rejection therapies and monitor treatment.

The company reported $33.8 million in total revenues for the quarter and said testing services revenues rose 68 percent year over year.

A bi-weekly listing of recent local coverage determinations from Medicare Administrative Contractors.

CareDx claims that Eurofins Viracor infringes on its patent related to noninvasive monitoring of organ transplant rejection through cell-free DNA analysis.

CareDx will use NanoString's new Human Organ Transplant panel to develop HistoMap, a gene expression profiling test to identify allograft rejection.

The index, which slightly underperformed the Dow Jones, had a smaller loss in August than in the previous month.

CareDx said it will add XynManagement's products to its digital solutions portfolio and integrate them with current offerings including OTTR.

The Medicare contractor has proposed to cover the non-invasive test for certain kidney and heart transplant patients.

The company reported $31.5 million in total revenues for the quarter and said testing services revenues rose 84 percent year over year.

Pages

GenomeWeb reports that Veritas Genetics is suspending its US operations.

A Brazilian-led team of researchers reports it has generated a sugarcane genome assembly that encompasses more than 99 percent of its genome.

Certain plasma proteins could be used to gauge a person's age and whether they are aging well, according to HealthDay News.

In Science this week: approach to measure microRNA targeting efficiency, strategy to conduct high-throughput chemical screens at single-cell resolution, and more.